The vascular endothelium is involved in the production of many important substances which are involved in cardiovascular Ž . pathophysiology. One such substance which is synthesised by, and stored in, endothelial cells is von Willebrand factor vWf . When released, vWf appears to mediate platelet aggregation and adhesion. Numerous clinical and experimental reports suggest that high vWf levels reflect damage to the endothelium or endothelial dysfunction. The close association between vWf and the processes of thrombus Ž . formation thrombogenesis or atherogenesis also suggests that high vWf levels may be a useful indirect indicator of atherosclerosis andror thrombosis. The availability of a useful marker of endothelial dysfunction may have potential clinical value. The measurement of such a marker can perhaps be a non-invasive way of assisting in clinical diagnosis or as an indicator of disease progression. High vWf levels have also been shown to have prognostic value in patients with ischaemic heart disease, peripheral vascular disease and inflammatory vascular disease. However, there is limited information that increased vWf is actually causal in the progression of vascular disease and that measures aimed at reducing vWf levels will be beneficial. In addition, interpretation of raised plasma vWf levels is complicated by the fact that vWf may be an acute phase reactant. Further research is indicated to explore the predictive value of this Ž . marker in population studies and, perhaps, therapeutic approaches in and the value of modulating vWf levels or function.
Introduction
It has been recognised for over 150 years that abnormalities in blood flow, vessel wall and blood components may Ž .w x contribute towards thrombosis Virchow's triad 1 . This simplified view is now modified by the recognition that Ž . the process of thrombus formation thrombogenesis requires complex interactions involving injury to the vascular endothelium, platelet adherence, aggregation and release, and clotting factor activation; this process eventually leads to thrombin generation and fibrin formation.
Under physiological conditions, the vascular endothelium produces many substances which are closely associated with haemostasis, fibrinolysis, the synthesis of growth factors, and the regulation of vessel tone and permeability. One such substance that is synthesised by, and stored in, ) Ž .
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Ž
. endothelial cells is von Willebrand factor vWf . As vWf release is increased when endothelial cells are damaged, vWf levels have been proposed as a possible indicator of w x endothelial dysfunction 2-4 . The presence of endothelial disturbance is pertinent as this may result in changes in the ability of the cell to participate adequately in both coagulation and fibrinolysis, thus predisposing to thrombus formaw x tion and atherosclerosis 5 . The availability of a useful index of endothelial dysfunction may therefore have potential value, as measurement of such a marker can be a non-invasive way of assisting in diagnosis, an indicator of disease progression and prognosis.
The known association between vWf, thrombogenesis and atherosclerotic vascular disease also suggests that high concentrations of vWf may be an indirect indicator of atherosclerosis andror thrombosis. vWf is also known to have an important function in platelet aggregation and w x adhesion 2 . However, vWf is a sensitive marker and levels can be influenced by many pathological conditions, w x including the acute phase response 6 .
Biochemistry and pathophysiology
vWf is a multimeric glycoprotein which is synthesised exclusively in endothelial cells and megakaryocytes. It has two functions: Firstly, this glycoprotein carries factor VIII in the circulation and is required for factor VIII stability in the plasma. By serving as the carrier for factor VIII, vWf Ž . may also coordinate formation of the fibrin and plateletrich thrombus at the site of endothelial cell injury. Secondly, this glycoprotein may mediate initial platelet adhesion to the subendothelium by linking to specific platelet Ž . membrane receptors glycoprotein Ib-IX complex and to constituents of subendothelial connective tissue. This is pertinent as damage to the vascular endothelium, perhaps secondary to hypertension, hyperlipidaemia or smoking, results in platelet aggregation and adhesion at the site of w x injury, and the activation of the coagulation cascade 7,8 . Through multiple functional domains, each vWf subunit Ž . has binding sites for collagen, heparin, glycoprotein GP Ib, GPIIbrIIIa and factor VIII.
The synthesis of vWf is complex and multiple steps are involved. Different molecular-weight multimers of vWf exist, with the high-molecular-weight multimers found in platelets and endothelial cells, which also have a higher Ž affinity for subendothelial cell matrix binding especially . to collagen than do the smaller vWf multimeric species w x 9 . This difference suggests that since the vWf multimers produced and secreted by endothelial cells in vitro and in vivo includes ultra-large vWf forms, the structure or type of circulating vWf may eventually become more important markers of endothelial cell injury, dysfunction or stimulation than absolute levels of plasma vWf antigen; present evidence is however limited.
The secretion of vWf is via constitutive and regulated Ž . pathways Fig. 1 , and the half-life of circulating vWf is w x 18 hours 10 . Constitutively secreted vWf is found in the basement membrane and free in the plasma. An additional pool is present in the storage granules of platelets and endothelial cells, which can be released in response to vascular injury. In cultured endothelial cells, 95% of synthesized vWf is secreted constitutively whilst the remaining is packaged in the storage granules, termed 'WeibelPalade bodies', which are analogous to the a granules w x seen in platelets 11 . The vWf multimers are thought to be represented by tubular structures, which are seen inside the Weibel-Palade bodies on electron microscopy; these are the large, high-molecular-weight vWf multimers that are w x most effective in mediating platelet binding 11,12 . Most of plasma vWf is derived from endothelial cells rather than from platelets under normal circumstances, suggesting that vWf is a good marker of endothelial w x dysfunction 13,14 . However, it is not clear if this also holds for every pathological situation. For example, acti-Ž . vated platelets and perhaps bone marrow megakaryocytes may occasionally contribute more to the circulating pool of vWf in certain thrombotic disorders, potentially making plasma vWf a less reliable index of endothelial dysfuncw x tion under these conditions 9,11 . Platelet vWf also tends to remain bound to the platelet surface after release from a Ž . granules. In vivo, the release rather than synthesis of vWf from storage pools is stimulated by the administration Ž of adrenaline, vasopressin or its analogue, DDAVP or . 1-desamino-8-D-arginine vasopressin and nicotinic acid, resulting in an increase in plasma vWf levels. In experimental situations, vWf release from storage granules can be stimulated by thrombin, fibrin, histamine and complew x ment proteins C5a-9 11 . As thrombin and fibrin are found at sites of vascular injury or damage, and histamine release and complement activation occur at sites of inflammation or injury, the release of the large vWf multimers from Ž storage granules rather than the constitutively secreted . pool results in a rapid response to vascular injury and w x endothelial damage 12 .
The critical role of vWf in coagulation is evident from the profound bleeding disorder that results from vWf Ž . w x deficiency von Willebrand's disease 15 . The system for the diagnosis and classification of von Willebrand's disease is complex, with more than 20 distinct variants dew x scribed 15 . Such vWf deficiency results in defective platelet adhesion and a secondary deficiency of factor VIII, both causing abnormal haemostasis; this may lead to less thrombogenesis and atherogenesis. In experimental work, for example, pigs with von Willebrand's disease have been shown to be protected from spontaneous and diet-induced w x aortic atherosclerosis and platelet thrombosis 16,17 . In man, the situation is unproven as patients with von Willebrand's disease are often treated with vWf-rich cryoprecipitate andror DDAVP to raise vWf levels, thus making it difficult to test this hypothesis. Some evidence is however provided by studies showing a lower-than-expected incidence of ischaemic heart disease in haemophiliac patients Ž who have a deficiency of factor VIII coagulant activity
. w x with normal levels of vWf 18 . Transplantation of bone marrow from a subject with von Willebrand's disease into a haemostatically normal patient also did not influence w x vWf levels 19 .
von Willebrand factor and platelet adhesion
The 'binding' or adhesion of platelets to the vessel wall, which is mediated by vWf at sites of vascular injury, appears to be one of the earliest events triggering formation of the platelet plug in thrombus formation. Circulating vWf does not bind to resting platelets in normal haemostasis. When the subendothelial matrix of the blood vessel wall is exposed, vWf binding to these matrix components promotes platelet aggregation and formation of a platelet w x plug 9,11 . In vitro, the shear rate is another influencing Ž factor, and at high shear rates similar to that seen in the . microvasculature , vWf becomes essential for platelet w x binding 9,20 .
Platelets adhere to vWf through glycoprotein IIbrIIIa receptors, which are usually available for binding only w x after platelet activation 20,21 . Glycoprotein IIbrIIIa is a member of the integrin family of adhesive proteins. This binding is dependent upon multimeric size with highmolecular-weight vWf having a higher affinity for the w x receptors than the low-molecular-weight vWf forms 22 . Modulation of this glycoprotein IIbrIIIa receptor binding by anti-glycoprotein IIbrIIIa receptor antibodies have shown clinical application in preventing restenosis after w x angioplasty 23 , and in initial studies in patients with w x unstable angina and myocardial infarction 24 .
However, despite the close relationship between vWf and platelets, established markers of platelet activation, such as b-thromboglobulin, do not correlate with levels of w x vWf 25 . In addition, aspirin, which is an inhibitor of platelet activity, does reduce b-thromboglobulin levels, but w x does not have any affect on vWf levels 26 . These observations support the hypothesis that plasma vWf does not arise from platelets.
vWf and ischaemic heart disease
There is a well-established association between vWf levels and ischaemic heart disease, suggesting a role for endothelial dysfunction in the pathogenesis of coronary artery disease. For example, increased concentrations of vWf are found in patients with previous myocardial infarcw x tion 27-30 . There is also an association between vWf w x with the clinical severity of angina 31 . No circadian variation in vWf levels is found, in contrast to a marked w x circadian variation in fibrinolytic variables 32 .
Sequential changes in vWf levels following acute myocardial infarction have been well documented. In the w x Ž study by Bridges et al. 33 , a significant increase by . 28% in vWf levels was demonstrated in patients who were reperfused at 90 minutes following thrombolytic therapy. Thus reperfusion in acute myocardial infarction Ž may also result in endothelial dysfunction thus releasing . w x vWf , as suggested by Giustolisi et al. 34 . Alternatively, reperfusion may 'wash out' vWf which was released before reperfusion in endothelium or endocardium which is infarcted or ischaemic. The mechanism for vWf release in acute myocardial infarction may be related to the release of free radicals which occurs following acute myocardial w x infarction and reperfusion 35 . Following thrombolytic Ž . therapy with tissue plasminogen activator t-PA , patients with angiographic patency demonstrate a fall in vWf at 24 hours post-thrombolysis, when compared to patients with w x an occluded artery 36,37 . In a study of patients undergoing percutaneous transluminal coronary angioplasty, there was a rise in vWf indicating endothelial injury 1 hour after inflation, which was associated with increased free radical w x activity 38 . Thus, one mechanism of endothelial disturbance which occurs with reperfusion with thrombolytic therapy or during angioplasty is likely to involve free radical generation.
vWf appears to be an index of increased risk for reinfarction and mortality in patients with angina and in survivors post-myocardial-infarction. In a prospective follow-up study of 123 survivors of myocardial infarction, high vWf levels were independent risk factors for both w x reinfarction and mortality 39 . This is consistent with results from an earlier study where patients who died within a year following myocardial infarction had signifiw x cantly higher concentrations of vWf 28 . In the Progetto Ž . Lombardo Atero-Trombosi PLAT study, vWf levels were a significant predictor for atherothrombotic events in paw x tients with angina pectoris 40 . Similarly, the large Euro-Ž . pean Concerted Action Against Thrombosis ECAT study, a prospective multicentre study of 3043 patients with angina pectoris, showed that levels of vWf, fibrinogen and tissue plasminogen activator were independent predictors of subsequent acute coronary syndromes after 2 years w x follow-up 41 . In a 16-year follow-up study of 1393 men, w x Meade et al. 42 reported that increased vWf levels were a significant risk factor for fatal ischaemic heart disease events. In addition, one early longitudinal population study also reported a trend for ischaemic heart disease events to increase with elevated concentrations of factor VIII and w x vWf levels 43 . By contrast, only one report showed no difference in vWf levels between survivors post-myocardial-infarction compared to controls, but these patients were generally younger than the studies previously disw x cussed 44 . In patients with ischaemic heart disease, vWf measured immediately after angioplasty is also predictive w x of restenosis 45 . Thus, the evidence that raised vWf levels have prognostic implications in patients with ischaemic heart disease appears persuasive.
The precise mechanism by which vWf increases cardiovascular risk in patients with angina or post-myocardial-infarction is unknown. Firstly, increased endothelial damage in coronary artery disease may result in both increased thrombin generation and higher levels of vWf. Alternatively, as vWf has a role both in adhesion and aggregation of platelets and in coagulation, the increased levels of vWf may increase the risk of thrombogenesis in patients with pre-existing vascular wall disease, thus leading to further reinfarctions. Furthermore, vWf may simply be a marker of more severe disease, and be without direct pathophysio-Ž . logical significance. However as discussed above , the relationship between vWf and coronary ischaemia may possibly in part reflect platelet activation with platelet-derived vWf, rather than purely endothelial dysfunction, since many coronary ischaemic syndromes are also associated with elevated levels of other platelet activation markers.
vWf and peripheral vascular disease
Levels of vWf are significantly higher in patients with peripheral vascular disease. In the Edinburgh Artery Study, for example, levels of vWf were significantly increased in w x 121 study cases compared with matched controls 46 . Increased levels of vWf also predicted poor outcome of w x infrainguinal bypass grafting 47 . In addition, Woodburn w x et al. 48 found that although surgical resolution of critical limb ischaemia in individual patients reduced levels of vWf, the reduction was not to levels in normal controls. This therefore suggests that endothelial cell damage in atherosclerosis is not confined to the symptomatic lesion w x but is widespread 48 . However, in a further study of 219 patients undergoing angiography, although vWf was again highly raised in patients relative to controls, such levels failed to correlate with a score of the severity of the peripheral vascular disease as compiled from angiogram w x results 49 . This provides additional support for the notion that raised vWf marks widespread endothelial cell damage.
High vWf levels have important prognostic implications in patients with peripheral vascular disease. In a 1-year follow-up of 617 patients with claudication, increased vWf carried with it a relative risk factor for a coronary event of w x 1.3 50 . However, this risk was exceeded by the relative risk conferred by cross linked fibrin degradation products Ž .
Ž . w x 2.6 and plasma viscosity 1.8 50 .
The increased levels of vWf in claudicants may be due w x to the cytotoxic products of activated neutrophils 51 . High vWf levels may be associated with a consumption of the antioxidant glutathione peroxidase, thus implying a possible role of cytotoxic reactive oxygen species prow x duced by activated neutrophils 52 . There is also an inverse relationship between vWf and glutathione peroxidase in patients with concomitant vascular disease andror w x hypercholesterolaemia 52 . Alternatively, increased vWf may result from elastase production from activated neuw x trophils, andror concomitant hypoxia 53 .
vWf and conditions associated with thromboembolism

Atrial fibrillation
Atrial fibrillation is a common cardiac arrhythmia which is associated with an increased risk of stroke and thromboembolism. Recent studies point towards a hypercoagulaw x ble state in this condition 54 . In a cross-sectional study of 85 patients with atrial fibrillation, plasma levels of vWf are significantly elevated and were not altered by the concomiw x tant use of aspirin or anticoagulation with warfarin 55 . Levels of vWf were independent of the underlying cause of atrial fibrillation and the presence of structural heart w x disease 55 . Similar findings were reported by Yamamoto w x et al. 56 , who found raised peripheral blood levels of Ž vWf in patients with mitral stenosis most of whom were . in atrial fibrillation , with similar vWf levels in the right and left atria. Although the precise mechanism for the increased vWf levels in atrial fibrillation is uncertain, Ž abnormalities in cardiac blood flow e.g., slow or sluggish . flow within the atria may be partly responsible, resulting in flow abnormalities and adding to endothelial disturbance in the pulmonary vasculature. w x In the study by Lip et al. 55 , there was also a positive correlation between plasma vWf and fibrin D-dimer, an index of fibrin turnover and thrombogenesis. The latter observation is in keeping with the association between Ž . blood vessel wall thus, endothelial abnormalities and Ž . thrombus formation as part of Virchow's triad .
Left Õentricular dysfunction
Patients with heart failure are at risk of thromboemw x bolism 57 . In a study of patients with ischaemic heart w x disease and cardiac dysfunction, Lip et al. 29 found that Ž those with left ventricular aneurysms as defined by ra-. dionuclide ventriculography had the highest levels of plasma vWf, and other prothrombotic markers such as fibrinogen and fibrin D-dimer. This finding may be explained by two possible mechanisms. Firstly, patients with the highest vWf levels were at highest cardiovascular risk, resulting in the largest myocardial infarctions, or recurrent w x infarctions 39 , thus resulting in the most cardiac 'damage' and subsequent aneurysm formation. Alternatively, these Ž patients have the greatest endothelial dysfunction as re-. flected by the high vWf levels , thus leading to greater intravascular thrombogenesis, consistent with the highest w x plasma D-dimer levels being found in these patients 29 .
Clinical and epidemiological studies on the risk of thromboembolism in patients with cardiac impairment do not however differentiate between the contribution of systolic and diastolic dysfunction to heart failure. This is pertinent as up to 30-40% of patients with congestive w x heart failure have normal systolic function 58 . Endothe- lial dysfunction may thus be related to abnormalities of diastolic function seen in ischaemic heart disease. In a Doppler echocardiographic study of 106 patients with ischaemic heart disease, we found no significant differences in vWf levels between patients with and without diastolic dysfunction; this was despite correcting for the interaction with systolic dysfunction when it was present in individual w x patients 59 . However, patients with the greatest systolic Ž . abnormalities with aneurysm formation had the highest w x vWf levels 59 .
CerebroÕascular disease
Increased vWf levels are well-recognised to be associw x ated with ischaemic cerebrovascular events 60-62 . Patients with thrombotic strokes have also been reported to have higher vWf levels compared to those with haemorw x rhagic strokes 63 . The possible mechanisms for the association between vWf and cerebrovascular events include endothelial dysfunction associated with cerebral thrombo-Ž . sis or other risk factors, such as hypertension or ischaemia-related release of vWf from infarcted tissue; the precise mechanism for this association, however, remains unknown. In a pilot study of 64 patients with acute stroke Ž . ictus -12 hours , we have recently demonstrated signifi-Ž . cant endothelial dysfunction with high vWf levels , which were associated with haemorrheological abnormalities Ž . fibrinogen levels and plasma viscosity and platelet dys-Ž function with raised soluble adhesion molecule P-selectin
. w x levels 64 . These abnormalities may act synergistically to contribute to the pathogenesis of acute stroke and its complications.
Venous thrombosis
Raised vWf levels have been associated with increased thromboembolic events, for example, in patients with deep w x venous thrombosis 62 . The prospective value of vWf in venous thromboembolism was shown in a study of patients after major abdominal surgery where high preoperative concentrations of vWf were associated with an increased w x risk of postoperative deep venous thrombosis 65 . Howw x ever, Koster et al. 66 found raised vWf in patients who had suffered a deep vein thrombosis, but this effect was almost totally explained by a close relationship with blood groups and factor VIII. Consequently, there may be no evidence of excessive endothelial cell damage in this disease.
vWf and pulmonary vascular disease
The pulmonary vasculature has significant influences on plasma vWf levels. For example, elevated plasma vWf has also been demonstrated in patients with elevated pulmonary vascular resistance and decreased cardiac output, w x irrespective of the presence of mitral stenosis 67 . In primary pulmonary hypertension, histological evidence of injury to pulmonary endothelial cells is associated with elevations of plasma vWf, thus contributing to the risk of thrombosis and a haemodynamically-induced increase in w x the endothelial release of vWf 68 .
vWf and diabetes
Abnormalities of vWf have also been demonstrated in diabetics and may be involved in the pathogenesis of w x diabetic vasculopathy 69-71 .
For example, a raised urinary albumin excretion in non-insulin-dependent diabetes is an index of early diabetic nephropathy that is also associated with increased w x vWf levels and a high risk of cardiovascular disease 71 . It is therefore considered that dysfunction of vascular endothelium may be one link between the microalbuminuria and atherosclerotic cardiovascular disease found in non-insulin-dependent diabetics. Similarly diabetics with w x neuropathy have significantly elevated vWf levels 72 .
In a population-based cross-sectional study, however, vWf levels were found to be unrelated to the metabolic w x factors involved in the insulin resistance syndrome 73 . Despite the apparently clear paradigm that patients with the poorest glycaemic control are at greatest risk of adw x verse cardiovascular risk, Steiner et al. 74 were unable to correlate vWf levels with either HbA1c or fructosamine in non-insulin-dependent diabetics.
vWf and hypertension
With age and hypertension, the role of the protective mechanisms of the endothelium diminish, and changes in Ž vasoactive endothelial factors such as endothelin, prosta-. glandins, etc. become more important for the maintenance w x of blood pressure and cardiovascular haemodynamics 75 . Plasma vWf may therefore be a marker for such endothelial dysfunction or disturbance in hypertension, in view of w x the increase in plasma vWf seen in vascular disease 76 .
Levels of vWf are significantly increased in patients with hypertension, but are normalised in patients in whom hypertension was successfully treated with antihypertenw x sive drugs 77 . We have recently demonstrated increased levels of plasma vWf, fibrinogen and the soluble adhesion Ž . molecule P-selectin a possible marker of platelet activity in patients with hypertension, which were significantly Ž correlated with diastolic blood pressure levels, but in w x. contrast to previous reports 77 levels of these markers were unrelated to whether or not antihypertensive treatment was used or good blood pressure control was achieved w x 78 . w x Varizi et al. 79 also reported high vWf levels in hypertensives, which were associated with diastolic blood pressure levels. In addition, there was a modest correlation to the left ventricular posterior wall and ventricular septum The latter is an index of hypertensive target-organ damage, and hypertensives with left ventricular hypertrophy are well-recognised to be at high risk of cardiovascular complications. Another index of hypertensive end-organ damage, Ž microalbuminuria defined as the excretion of urine albu-. min between 20 and 200 mgrmin is also related to endothelial dysfunction, suggesting that microalbuminuria reflects systemic dysfunction of the vascular endothelium w x 80 . When compared to hypertensives without microalbuminuria or controls, vWf levels were significantly higher w x in hypertensive patients with microalbuminuria 80 .
In pregnancy-induced hypertension and pre-eclampsia, mean vWf levels were significantly higher compared to healthy pregnant women, and levels were correlated to the w x severity of the condition 81,82 . There was also an excess of large, medium and small sized vWf multimers in the patients with pregnancy-induced hypertension, perhaps rew x flecting endothelial injury 82 . This may play a role in the microangiopathy observed in the disease.
Although endothelial dysfunction or damage can be present as a result of hypertension, others have considered that endothelial damage may actually promote hyperw x tension 83 . The presence of endothelial damage may be one mechanism by which patients with hypertension are at risk of thrombogenesis and atherogenesis; this is reflected by the observation that whilst the arterial tree is exposed to increased pressure flow, paradoxically the complications of hypertension are mainly thrombotic rather than haemorrhagic.
vWf and inflammatory vascular disease
Elevated vWf levels have been demonstrated in patients with inflammatory vascular disease and associated disorders, including vasculitis, Sjogren's syndrome, Felty's synw x drome, giant cell arteritis and polyarteritis nodosa 84 . For example, studies in patients with Raynaud's phenomenon, which included patients with and without atherosclerosis or connective tissue disease, showed high levels of vWf in w x all patients 85 . Patients with systemic sclerosis and Raynaud's phenomenon also have increased vWf, especially if w x diffuse disease was present 86 .
Two serial studies in patients with inflammatory vascuw x lar disease are of note: Wallberg-Jonsson et al. 87 measured vWf and two non-specific endothelial markers-tis-Ž . sue plasminogen activator tPA and plasminogen activator Ž . inhibitor PAI -in 74 patients with rheumatoid arthritis. Two years later, increased vWf, but not tPA or PAI, remained as a multivariate predictor of the patients who suffered a thromboembolic event. We have also shown that increased vWf predicts death in patients with systemic w x sclerosis 88 .
With improvements in immunosuppressive therapy, Ž . fewer patients with systemic lupus erythematosus SLE are dying of the autoimmune disorder, but, instead, vascular complications have become more common. vWf may have a role in the pathogenesis of cardiovascular disorders in these patients, as levels are also significantly increased w x in such patients 89,90 . For example, immunoglobulins Ž . especially IgG from patients with SLE can stimulate vWf release and this may be implicated in the thrombotic w x events observed in these conditions 91 . In addition, endothelial cell dysfunction has been related to the presence w x of anti-endothelial-cell antibodies 92 and anti-phospholi-Ž . pid antibodies which cross-react with the endothelium w x 93 . These antibodies may result in endothelial cell damage by various mechanisms such as complement activation Ž . w x perhaps by immune complex formation 94 , antibodyw x dependent cell cytotoxicity 95 or by the inhibition of w x prostacyclin production 96,97 . The diversity of possible mechanisms is mirrored by the wide spectrum of autoantiw x bodies found in SLE. A study by Lindsey et al. 91 demonstrated that immunoglobulin G from patients with SLE or antiphospholipid syndrome was capable of stimulating vWf release and this ability may be implicated in thombogenesis. However, there was no correlation between either anti-endothelial or anti-cardiolipin antibodies w x and vWf release 91 .
vWf and homocysteinuria
Homocysteinuria is an inborn error of metabolism associated with thrombotic and vascular complications, where w x excess homocysteine is toxic to the endothelium 98 . This is demonstrated in in-vitro studies where homocysteine inhibits vWf processing and secretion by preventing intraw x cellular transport 99 . Homocysteine and cysteine also w x promote the detachment of endothelial cells in vitro 100 , and the former is cytotoxic to endothelial cells in vitro and w x will enhance the release of vWf 101 . In addition, hyper-Ž . homocyst e inaemia is a risk factor for intermittent claudiw x Ž . cation 102 , and as discussed above high vWf levels are found in such patients, with important prognostic implications.
Possible measures to alter vWf levels
It follows from the above that if high levels of vWf are to be avoided, then steps should be taken to do so. There Ž . are two approaches: i to treat the risk factors for athero-Ž . sclerosis, and ii to develop new agents to inhibit the w x activity of vWf 103 . As yet, there are no definitive methods of therapeutically altering plasma vWf levels. There is also no evidence that measures to reduce circulating vWf will have beneficial effects in modifying cardiovascular risk.
Treatment of the risk factors of atherosclerosis
Since vWf is increased in each of the four major risk Ž factors for atherosclerosis hypertension, hypercholesterol- . aemia, smoking and diabetes , then modifying these facw x tors may perhaps reduce vWf 104 . For example, lower levels of vWf may be obtained in diabetics who are able to w x control their ketoacidosis 70 . Clinic population studies have also indicated that patients whose hypertension has been successfully treated have lower vWf than those similar patients whose hypertension has yet to be brought w x under control 77 . Similarly, patients with coronary artery disease who had been on a strict diet for 3 years to reduce their cholesterol had lower levels of vWf than a similar w x cohort who were not intensively dieted 105 . In this study, levels of vWf correlated with both total cholesterol and w x inversely with dietary polyunsaturated fats 105 . This Ž supports the hypothesis that certain lipoproteins especially . oxidised low-density lipoproteins are cytotoxic to the endothelial cells in vitro and so may be important in w x atherogenesis 106 . The inverse correlation between dietary polyunsaturated fats and vWf implies that the former are beneficial to the endothelium, which is consistent with w x previous observations 107 and epidemiological studies relating adipose tissue fatty acid analysis to coronary heart w x disease 108 . There is also preliminary evidence that conventional lipid-lowering therapy will reduce vWf in patients who are hypercholesterolaemic with or without w x symptomatic vascular disease 109 . The control of other risk factors, including obesity, and abstention from smokw x ing and control of hypertension 14,110 may reduce vWf levels.
DeÕelopment of new drugs
The central role of vWf in thrombogenesis has made it a target for research into antithrombotic therapies centred on antibodies, peptides, or other compounds that inhibit vWf function, which have been suggested as potential new w x anticoagulants 103 . This inhibition may be possible at a number of sites on the vWf molecule. Engineered heparins can inhibit vWf-dependent platelet aggregation and vWfw x w x platelet binding 111 . Dardik et al. 112 have demonstrated reduced platelet binding to an extracellular matrix with a recombinant GPIb-binding peptide. Aurin tricarboxylic acid inhibits ristocetin-induced, vWf-mediated w x platelet aggregation 113 . All these approaches have potential as exciting new tools to minimise the procoagulant activity of vWf and may therefore be future therapeutic agents.
Are raised vWf levels in vascular disease a cause or effect?
Until recently, our understanding of the role of vWf in vascular disease has been based on cross-sectional studies and epidemiologic observations. Elevated plasma vWf levels are consistently associated with various cardiovascular Ž disorders coronary, cerebrovascular and peripheral artery . disease and the risk of vascular events. It has been suggested that these associations may be explained by a Ž reactive or secondary rise in plasma vWf and other . haemostatic factors either as an acute phase response or as an atherosclerosis-related 'haematological stress synw x drome' 114 . The processes of thrombogenesis and atherogenesis have certain similarities to inflammatory disease that develop as a result of metabolic, physical and environmental injury to blood vessels; thus the elevations in plasma vWf levels may reflect the severity of vascular disorders as a secondary phenomenon rather than act as a true prognostic factor. Indeed, vWf may have some characteristics of an acute phase reactant, being increased in w x infections, acute inflammation and malignancy 6 . For example, significant elevations in vWf have been reported Ž in patients with active inflammatory processes such as giant cell arteritis, polymyalgia rheumatica and in malig-
. w x nancy with metastases 115,116 . Thus, interpretation of raised vWf levels may be complicated by its behaviour as an acute phase reactant. Nevertheless, measurement of vWf levels may be more useful than that of acute phase reactants such as C-reactive protein or the ESR as vWf is probably more 'specific', and may imply vascular disease Ž . unlike the CRP or ESR .
Raised plasma vWf levels are also known to precede cardiovascular events. This is indicated by the possible prognostic value of vWf, for example, in predicting acute w x coronary syndromes in patients with angina 41 , reinfarcw x tion following myocardial infarction 39 and in patients w x with peripheral vascular disease 47,50 , as discussed above. In addition, there is also an association between w x vWf with the clinical severity of angina 31 . In patients with inflammatory vascular disease, such as rheumatoid arthritis and systemic sclerosis, vWf levels have prognostic implications, with high levels predicting mortality, disease w x progression and cardiac events 87,88,116 . However, whilst elevated vWf levels have been shown to precede cardiovascular events, this may merely reflect the severity of the underlying disease and causation is not necessarily implied. For example, high vWf levels are found following endothelial injury by cardiovascular risk factors such as smoking, hypertension or hyperlipidaemia.
There is experimental evidence that vWf levels may be increased by glucocorticoids and cytokines such as interleukin-1 and tumour necrosis factor which are produced by w x monocytes and macrophages 117,118 . However, since vWf is also an acute phase protein, increased levels may simply reflect endothelial activation or stimulation, and not w x endothelial dysfunction 6 . Thus, occlusive disease of arteries by thrombus may cause a reactive increase in vWf. The well-established increases in plasma vWf levels in many cardiovascular disorders and atherosclerosis risk factors are however not always associated with an active w x acute phase response 14,76-78 .
The precise mechanism for the elevated vWf in cardiovascular disorders is therefore still uncertain. Although a cytokine-mediated increase in synthesis is likely to be the common pathway, the possibilities that high vWf levels in vascular disorders may be due to a combination of increased secretion from stored pools, increased synthesis de noÕo or release from endothelial cell damage still remains. The initiating stimulus for vWf release or synthesis in patients with vascular disease is also uncertain, and may Ž include various cardiovascular risk factors smoking, hy-. perlipidaemia, etc. , oxygen free radicals or hypoxia secondary to ischaemia.
Conclusion
Many case-controlled studies support the hypothesis that high concentrations of vWf are an index of atherosclerosis or of an increased risk of thrombogenesis or both. Concerns remain, however, whether the elevations in vWf in vascular disorders are relevant or simply an epiphenomenon. Recent reports also suggest that raised vWf levels have important prognostic implications in ischaemic heart disease and peripheral vascular disease. vWf may therefore be a good marker for endothelial dysfunction in a variety of vascular disorders. Further research is indicated to explore the predictive value of this marker in population Ž studies and perhaps therapeutic approaches in and the . value of modulating vWf levels or function. However, some of these future directions also await a better understanding of the transcriptional and translational regulation of vWf biosynthesis and of vWf secretion.
Note added in proof
Increased vWf due to smoking is reversible upon cessaw x tion 119 . This further supports the hyopthesis that increased vWf precedes atherosclerosis and that levels fall by treatment of risk factors. 
